The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular degeneration.